Effects of Lenvatinib combined with transcatheter arterial chemoembolization in treatment of patients with advanced liver cancer
Objective:To observe effects of Lenvatinib combined with transcatheter arterial chemoembolization(TACE)in treatment of patients with advanced liver cancer.Methods:A prospective study was conducted on 66 patients with advanced liver cancer admitted to this hospital from August 2021 to July 2023.According to the random number table method,they were divided into control group and study group,33 cases in each group.The control group was treated with TACE,while the study group was treated with Lenvatinib on the basis of that of the control group.Both groups were treated for 3 months.The clinical efficacy,the liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL)]levels,the serological indexes[interleukin-1(IL-1),vascular endothelial growth factor(VEGF),alpha-fetoprotein(AFP)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR)of the study group was 93.94%(31/33),which was higher than 75.76%(25/33)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of ALT,AST and TBIL in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-1,VEGF and AFP in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as bone marrow suppression,gastrointestinal discomfort,alopecia and fever between the two groups(P>0.05).Conclusions:Lenvatinib combined with TACE in the treatment of the patients with advanced liver cancer can improve the DCR and reduce the levels of liver function indexes and serological indexes.Moreover,it is superior to single TACE treatment.
AdvanceLiver cancerTranscatheter arterial chemoembolizationLenvatinibLiver functionSerologyDisease control rateAdverse reaction
万方数据
维普
